It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2010
  5. FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography

March 12, 2010

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it acquired additional approval of indications, dosage and administration for the MRI oral GI contrast agent, FerriSeltz® powder 20%, for GI negative imaging in cholangiopancreatography in abdominal magnetic resonance and computed tomography on March 12, 2010.


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases